Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
- DOI
- 10.1053/j.gastro.2021.06.015
- Published
- 2021 Oct
- Container
- Gastroenterology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1053/j.gastro.2021.06.015,
title = {Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).},
author = {Peyrin-Biroulet L and Loftus EV Jr and Colombel JF and Danese S and Rogers R and Bornstein JD and Chen J and Schreiber S and Sands BE and Lirio RA},
year = {2021},
journal = {Gastroenterology},
doi = {10.1053/j.gastro.2021.06.015},
url = {https://doi.org/10.1053/j.gastro.2021.06.015}
}RIS
TY - JOUR TI - Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). AU - Peyrin-Biroulet L AU - Loftus EV Jr AU - Colombel JF AU - Danese S AU - Rogers R AU - Bornstein JD AU - Chen J AU - Schreiber S AU - Sands BE AU - Lirio RA PY - 2021 JO - Gastroenterology DO - 10.1053/j.gastro.2021.06.015 UR - https://doi.org/10.1053/j.gastro.2021.06.015 ER -
APA
L, P., Jr, L. E., JF, C., S, D., R, R., JD, B., J, C., S, S., BE, S., & RA, L. (2021). Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).. Gastroenterology. https://doi.org/10.1053/j.gastro.2021.06.015
Source records
- pubmed · retrieved 2026-11-10T12:24:23.617Z